Changes in the Pharmaceutical Market Due to Healthcare Cost Containment, Generic Drug Adoption and Other Factors
First written in FY2017-Q1. 12 of 13 entries say "Restated". Latest entry: FY2021.
The whole theme swung hardest in 2018: 20 of 65 companies on the "Worse" side.
47 other companies' latest entry also says "Restated".
- FY2021RestatedAnnual report
「In the pharmaceutical market, healthcare cost-containment measures have been strengthened in the countries of Japan, the United States and Europe, which have driven market growth to date. The pharmaceutical market is expected to undergo changes going forward, including the expansion of emerging markets and the wider adoption of generic drugs.」
The company continues to identify changes in the pharmaceutical market driven by healthcare cost-containment measures, the spread of generic drugs and the expansion of emerging markets. - FY2020RestatedAnnual report
「In the pharmaceutical market, healthcare cost-containment measures have been strengthened in the countries of Japan, the United States and Europe, which have driven market growth to date. The pharmaceutical market is expected to undergo changes going forward, including the expansion of emerging markets and the wider adoption of generic drugs.」
The company continues to recognize changes in the pharmaceutical market driven by healthcare cost-containment measures, the spread of generic drugs and the expansion of emerging markets. - FY2020-Q3RestatedAnnual report
「In the pharmaceutical market, healthcare cost-containment measures have been strengthened in the countries of Japan, the United States and Europe, which have driven market growth to date. The pharmaceutical market is expected to undergo changes going forward, including the expansion of emerging markets and the wider adoption of generic drugs.」
The company continues to recognize changes in the pharmaceutical market driven by healthcare cost-containment measures, the spread of generic drugs and the expansion of emerging markets. - FY2020-Q2RestatedAnnual report
「In the pharmaceutical market, healthcare cost-containment measures have been strengthened in the countries of Japan, the United States and Europe, which have driven market growth to date. The pharmaceutical market is expected to undergo changes going forward, including the expansion of emerging markets and the wider adoption of generic drugs.」
The company continues to recognize changes in the pharmaceutical market driven by healthcare cost-containment measures, the spread of generic drugs and the expansion of emerging markets. - FY2020-Q1RestatedAnnual report
「In the pharmaceutical market, healthcare cost-containment measures have been strengthened in the countries of Japan, the United States and Europe, which have driven market growth to date. The pharmaceutical market is expected to undergo changes going forward, including the expansion of emerging markets and the wider adoption of generic drugs.」
The company continues to recognize changes in the pharmaceutical market driven by healthcare cost-containment measures, the spread of generic drugs and the expansion of emerging markets. - FY2019-Q3RestatedAnnual report
「In the pharmaceutical market, healthcare cost-containment measures have been strengthened in the countries of Japan, the United States and Europe, which have driven market growth to date. The pharmaceutical market is expected to undergo changes going forward, including the expansion of emerging markets and the wider adoption of generic drugs.」
The company continues to recognize changes in the pharmaceutical market driven by healthcare cost-containment measures, the spread of generic drugs and the expansion of emerging markets. - FY2019-Q2RestatedAnnual report
「In the pharmaceutical market, healthcare cost-containment measures have been strengthened in the countries of Japan, the United States and Europe, which have driven market growth to date. The pharmaceutical market is expected to undergo changes going forward, including the expansion of emerging markets and the wider adoption of generic drugs.」
The company continues to recognize changes in the pharmaceutical market driven by healthcare cost-containment measures, the spread of generic drugs and the expansion of emerging markets. - FY2019-Q1RestatedAnnual report
「In the pharmaceutical market, healthcare cost-containment measures have been strengthened in the countries of Japan, the United States and Europe, which have driven market growth to date. The pharmaceutical market is expected to undergo changes going forward, including the expansion of emerging markets and the wider adoption of generic drugs.」
The company continues to recognize changes in the pharmaceutical market driven by healthcare cost-containment measures, the spread of generic drugs and the expansion of emerging markets. - FY2018-Q3RestatedAnnual report
「In the pharmaceutical market, healthcare cost-containment measures have been strengthened in the countries of Japan, the United States and Europe, which have driven market growth to date. The pharmaceutical market is expected to undergo changes going forward, including the expansion of emerging markets and the wider adoption of generic drugs.」
The company continues to recognize changes in the pharmaceutical market driven by healthcare cost-containment measures, the spread of generic drugs and the expansion of emerging markets. - FY2018-Q2RestatedAnnual report
「In the pharmaceutical market, healthcare cost-containment measures have been strengthened in the countries of Japan, the United States and Europe, which have driven market growth to date. The pharmaceutical market is expected to undergo changes going forward, including the expansion of emerging markets and the wider adoption of generic drugs.」
The company continues to recognize changes in the pharmaceutical market driven by healthcare cost-containment measures, the spread of generic drugs and the expansion of emerging markets. - FY2017RestatedAnnual report
「In the pharmaceutical market, healthcare cost-containment measures have been strengthened in the countries of Japan, the United States and Europe, which have driven market growth to date. The pharmaceutical market is expected to undergo changes going forward, including the expansion of emerging markets and the wider adoption of generic drugs.」
The company continues to identify changes in the pharmaceutical market driven by healthcare cost containment, the spread of generic drugs and the expansion of emerging markets. - FY2017-Q3RestatedAnnual report
「In the pharmaceutical market, healthcare cost-containment measures have been strengthened in the countries of Japan, the United States and Europe, which have driven market growth to date. The pharmaceutical market is expected to undergo changes going forward, including the expansion of emerging markets and the wider adoption of generic drugs.」
The company continues to identify changes in the pharmaceutical market driven by healthcare cost-containment measures, the spread of generic drugs and the expansion of emerging markets. - FY2017-Q1First statedAnnual report
「In the pharmaceutical market, healthcare cost-containment measures have been strengthened in the countries of Japan, the United States and Europe, which have driven market growth to date. The pharmaceutical market is expected to undergo changes going forward, including the expansion of emerging markets and the wider adoption of generic drugs.」
The company identifies changes in the future pharmaceutical market driven by healthcare cost-containment measures, the spread of generic drugs and the expansion of emerging markets as risks.